Excitotoxicity in acute and chronic neurodegeneration

Current Opinion in Central and Peripheral Nervous System Investigational Drugs

Volumn 2, Issue 4, 2000, Pages 403-416

  Budd, S L ^a   Rao, T S ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

Apoptosis; Glutamate receptors; Neurodegeneration; Neuroprotection

Indexed keywords

2 (8,9 DIOXO 2,6 DIAZABICYCLO[5.2.0] 1(7) NONENYL) ETHYLPHOSPHONIC ACID; 2 CARBOXYLIC ACID 4,6 DICHLORO 1H INDOLE 3 [(2 OXO 1 PHENYL 3 PYRROLIDENE)METHYL]; 3,3 BIS(3 FLUOROPHENYL) N METHYLPROPYLAMINE; 4,5 DIHYDRO 1 IMIDAZO 1 METHYL 4 OXO [1,2A] QUINOXALINE 7 TRIFLUOROMETHYL 2 CARBONIC ACID; 6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; AMPA RECEPTOR AGONIST; AMPA RECEPTOR ANTAGONIST; ANIRACETAM; CONANTOKIN G; EGLUMETAD; FLUPIRTINE; GACYCLIDINE; GAVESTINEL; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; IGT 440103; IONOTROPIC RECEPTOR; IRAMPANEL; LANICEMINE; MEMANTINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; OPIATE AGONIST; OPIATE ANTAGONIST; REMACEMIDE; RILUZOLE; SODIUM CHANNEL BLOCKING AGENT; TALAMPANEL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CELL DEATH; CLINICAL TRIAL; HUMAN; MENTAL DISEASE; NERVE CELL; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PAIN; PATHOGENESIS; REVIEW;

EID: 0033866592     PISSN: 1464844X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. The changing landscape of ischemic brain injury mechanisms
2. Cerestat and other NMDA antagonists in ischemic stroke
3. Neuroprotective activity of the potent and selective mGluR1a metabotropic glutamate receptor antagonist, (+)2-methyl-4-phenylcarboxyphenylglycine (LY367385): A comparison with LY357366, a broad spectrum antagonist with equal affinity for mGluR1a and mGluR5 receptors
4. Metabotropic glutamate receptors: A new target for the therapy of neurodegenerative disorders?
5. Caspases: Enemies within
6. The release and uptake of excitatory amino acids
7. Glial contributions to excitatory neurotransmission in cultured hippocampal cells
8. The excitatory amino acid receptors: Their classes, pharmacology, and distinct properties in the function of the central nervous system
9. Pharmacology and functions of metabotropic glutamate receptors
10. Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: Pharmacological characterisation
11. Glutamate neurotoxicity in vitro: Antagonist pharmacology and intracellular calcium concentrations
12. Serum and depolarizing agents cause acute neurotoxicity in cultured cerebellar granule cells: Role of the glutamate receptor responsive to N-methyl-D-aspartate
13. Combined oxygen and glucose deprivation in cortical cell culture: Calcium-dependant and calcium-independent mechanisms of neuronal injury
14. NMDA receptors: From genes to chanels
15. Developmental and regional expression pattern of a novel NMDA receptor-like subunit (NMDAR-L) in the rodent brain
16. Cloning and characterization of chi-1: A developmentally regulated member of a novel class of the ionotropic glutamate receptor family
17. Alternative splicing generates functionally distinct N-methyl-D-aspartate receptors
18. Heteromeric NMDA receptors: Molecular and functional distinction of subtypes
19. Molecular diversity of the NMDA receptor channel
20. Ifenprodil discrimanates subtypes of N-methyl-D-aspartate receptors: Selectivity and mechanisms at recombinant heteromeric receptors
21. Increased NMDA current and spine density in mice lacking the NMDA receptor subunit NR3A
22. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy
23. Structure and function of the NMDA receptor channel
24. Neuroprotective effects of MK-801 in vivo: Selectivity and evidence for delayed degeneration mediated by NMDA receptor activation
25. Protection of CA1 pyramidal cell function by MK-801 following ischaemia in the gerbil
26. Global ischemia induces downregulation of Glur2 mRNA and increases AMPA receptor-mediated Ca2+ influx in hippocampal CA1 neurons of gerbil
27. Selective blockade of mgluR5 metabotropic glutamate receptors protects against rat hepatocytes against hypoxic damage
28. Synaptic structure: Glutamate receptors connected by shanks
29. Activation of grpup I mGluRs potentiae NMDA responses in rat hippocampal slices
30. Potentiation of a metabotropic glutamatergic response following NMDA receptor activation in rat hippocampus
31. Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems
32. Activation of hippocampal metabotropic excitatory amino acid receptors lead to seizures and neuronal damage
33. Activation of metabotropic glutamate receptors coupled to inositol phospholipid hydrolysis amplifies NMDA-induced neuronal degeneration in cultured cortical cells
34. Activation of group I metabotropic glutamate receptors expressed in glial cells enhances excitotoxicity in neuronal cell cultures
35. Activation of metabotropic glutamate receptor subtype mGluR1 contributes to post-traumatic neuronal injury
36. Glutamate-induced neuron death requires mitochondrial calcium uptake
37. 2+ accumulaton in cortical cell culture correlates with subsequent neuronal degeneration
38. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds
39. Mitochondria and neuronal survival
40. Apoptosis and necrosis: Two distinct event induced, respectively, by mild and intense insults with NMDA or nitric oxide/superoxide in cortical cell cultures
41. Ions and energy in mammalian brain
42. Extracellular glutamate during focal cerebral ischemia in rats: Time course and calcium dependency
43. Ischemic cell death in brain neurons
44. Functional N-methyl-D-aspartate receptors in O-2A progenitor cells: A critical role in regulating polysialic acid neural cell adhesion molecule expression and cell migration
45. News on glutamate receptors in glial cells
46. AMPA-kainate subtypes of glutamate receptor in rat cerebral microglia
47. Localization of metabotropic glutamate receptor type 2 in the human brain
48. Expression and signaling of Group I metabotropic glutamate receptors in astrocytes and microglia
49. Cloning and functional expression of alternative spliced variants of human metabotropic glutamate receptor 8
50. Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis
51. Regionally selective effects of NMDA receptor antagonists against ischemic brain damage in the gerbil
52. Neuroprotective effect of YM90K, an AMPA-receptor antagonist, against delayed neuronal death induced by transient global cerebial ischemia in gerbils and rats
53. N-Methyl-D-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain
54. First observations of the safety and tolerability of a competitive antagonist to the glutamate NMDA receptor (CGS 19755) in patients with severe head injury
55. Pathobiology of ischaemic stroke: An integrated view
56. Dose escalation study of the NMDA glycine-site antagonist licostenel in acute ischemic stroke
57. Glaxo Wellcome breaking new ground
58. ZK200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma
59. BIIR 561 CL: A novel combined antagonist of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors and voltage-dependent sodium channels with anticonvulsive and neuroprotective properties
60. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease
61. Dextromethorphan improves levadopa-induced dyskinesias in Parkinson's disease
62. Improved cognition in Alzheimer's disease with short-term D-cycloserine treatment
63. Protection with metabotropic glutamate 1 receptor antagonists in models of ischemic neuronal death: Time course and mechanisms
64. Biochemical and electrophysiological studies on (S)-(+)-2-(3'-carboxybicyclo[1.1.1]pentyl)-glycine (CBPG), a novel mGluR5 agonist endowed with mGluR1 antagonist activity
65. Evidence against a permissive role of the metabotropic receptor I in acute toxicity
66. Neuroprotective effects of a systemically available group II metabotropic receptor agonist LY354740 in gerbil model of global ischemia
67. LY379268, a potent and selective group II metabotropic glutamate receptor agonist, is neuroprotective in gerbil global, but not focal, cerebral ischemia
68. Neuroprotection by metabotropic glutamate receptor glutamate receptor agonists: LY354740, LY379268 and LY389795
69. Selective activation of group II mGluRs with LY354740 does not prevent neuronal excitotoxicity
70. (R,S)-4-phosphonophenylglycine, a potent and selective group III metabotropic glutamate receptor agonist is anticonvulsive and neuroprotective in vivo
71. Reversal of neurodegenerative processes by selective modulation of group I or group III metabotropic receptor subtypes
72. Distinct influence of the group III metabotropic glutamate receptor agonist(R,S)-4-phosphonophenylglycine [(R,S)-PPG] on different forms of neuronal damage
73. Neuroprotective effects of group III mGluRs in traumatic neuronal injury
74. Loss of tyrosine hydroxylase immunoreactivity in dendrites is a sensitive index of kainic acid-induced damage in rat substantia nigra neurons in vivo
75. Mitochondria, free radicals, and neurodegeneration
76. Glutamate becomes neurotoxic via the N-methyl-D-aspartate receptor when intracellular energy levels are reduced
77. Hemiparkinsonism in monkeys after unilateral caudate nucleus infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Behavior and histology
78. Selective vulnerability of the CA1 region of hippocampus to the indirect excitotoxic effects of malonic acid
79. Excitotoxin lesions in primates as a model for Huntington's disease: Histopathologic and neurochemical characterization
80. 3-Nitropropionic acid produces striatum selective lesions accompanied by iNOS expression
81. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man
82. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity
83. Reversal of neurodegenerative process by selective blockade of metabotropic glutamate receptor subtype 5
84. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: Behavioral and immunohistochemical studies
85. Physiological role of multiple mGluR subtypes in rat basal ganglia
86. The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intracerebroventricular administration in the reserpine-treated rat
87. Macrophage recognition of cells undergoing programmed cell death (apoptosis)
88. Sequential changes of programmed cell death in developing fetal mouse limbs and its possible roles in limb morphogenesis
89. Apoptosis: Molecular regulation of cell death
90. Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis
91. Pivotal role of a DEVD-sensitive step in etoposide-induced and Fas-mediated apoptotic pathways
92. Activation of the CPP32 apoptotic protease by distinct signaling pathways with differential sensitivity to Bcl-xL
93. Induction of DNA fragmentation after 10 to 120 minutes of focal cerebral ischemia in rats
94. Apoptotic DNA fragmentation in the rat cerebral cortex induced by permanent middle cerebral artery occlusion
95. Inhibition of interleukin 1beta converting enzyme family proteases reduces ischemic and excitotoxic neuronal damage
96. Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family
97. Ultrastructural morphological changes are not characteristic of apoptotic cell death following focal cerebral ischaemia in the rat
98. Histochemical detection of apoptosis in Parkinson's disease
99. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons
100. On the question of apoptosis in the parkinsonian substantia nigra
101. Immunohistochemical evidence for apoptosis in Alzheimer's disease
102. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes
103. Evidence for apoptotic cell death in Huntington disease and excitotoxic animal models
104. Neuronal death in amyotrophic lateral sclerosis is apoptosis: Possible contribution of a programmed cell death mechanism
105. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: A cautionary note
106. DNA fragmentation in human substantia nigra: Apoptosis or perimortem effect?
107. Activation of neuronal caspase-3 by intracellular accumulation of wild-type Alzheimer amyloid precursor protein
108. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death
109. Bcl-xl-specific antibody labels activated microglia associated with Alzheimer's disease and other pathological states
110. Somatic expansion of the (CAG)n repeat in Huntington disease brains
111. Cellular mechanisms of beta-amyloid production and secretion
112. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease
113. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates
114. Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases
115. Altered cleavage and secretion of a recombinant beta-APP bearing the Swedish familial Alzheimer's disease mutation
116. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a 'humanized' Abeta sequence
117. Neuronal cell death
118. Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice
119. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
120. Ordering the cytochrome c-initiated caspase cascade: Hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner
121. Cytosolic redistribution of cytochrome C after transient focal cerebral ischemia in rats
122. Survival- and death-promoting events after transient cerebral ischemia: Phosphorylation of Akt, release of cytochrome C and activation of caspase-like proteases
123. Localization of Fas antigen mRNA induced in postischemic murine forebrain by in situ hybridization
124. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
125. Bax antisense oligonucleotides reduce axotomy-induced retinal ganglion cell death in vivo by reduction of Bax protein expression
126. Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia
127. Long-term effect of inhibition of ced 3-like caspases on the survival of axotomized retinal ganglion cells in vivo
128. Bcl-2 gene therapy exacerbates excitotoxicity
129. Selective inhibition of NAALDase, which converts NAAG to glutamate, reduces ischemic brain injury
130. Defining post-stroke recovery: Implications for design and interpretation of drug trials
131. Mapping clinically relevant plasticity after stroke